Crossmark

Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo

Crossref DOI link: https://doi.org/10.1007/s00262-022-03331-0

Published Online: 2022-12-01

Published Print: 2023-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Martomo, Stella A. https://orcid.org/0000-0002-0725-7672
Patel, Jeegar
License Information

Text and Data Mining valid from 2022-12-01

Version of Record valid from 2022-12-01
More Information

Article History

Received: 24 September 2022

Accepted: 15 November 2022

First Online: 1 December 2022

Declarations

:

: All authors are/were employed by Kadmon Corporation. This study was sponsored by Kadmon Corporation.

: All in vivo experiments were conducted in an accredited institution with approved animal protocols. In vivo experiments were done according to the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of WuXi AppTec in accordance with all standards of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and of Sanofi policies (tumor volumes, transgenic mice).

Document is current

Any future updates will be listed below